Breaking Finance News

Peregrine Pharmaceuticals (NASDAQ:PPHM) has been upgraded to Hold in a statement by ValuEngine earlier today.

Having a price of $0.57, Peregrine Pharmaceuticals (NASDAQ:PPHM) traded 2.61% higher on the day. With the last close down -23.71% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.04% over the same period. PPHM has recorded a 50-day average of $3.42 and a two hundred day average of $4.13. Trade Volume was up over the average, with 323,516 shares of PPHM changing hands over the typical 288,778

ValuEngine has upgraded Peregrine Pharmaceuticals (NASDAQ:PPHM) to Hold in a statement released on 6/20/2017.

Recent Performance Chart

Peregrine Pharmaceuticals (NASDAQ:PPHM)

Peregrine Pharmaceuticals has with a one year low of $1.96 and a one year high of $5.78 and has a market capitalization of $0.

General Company Details For Peregrine Pharmaceuticals (NASDAQ:PPHM)

Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company's subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.